This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

A 28-Week, Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia

John M. Kane, Olawale Osuntokun, Ludmila A. Kryzhanovskaya, Wen Xu, Virginia L. Stauffer, Susan B. Watson, and Alan Breier

Published: March 24, 2009

Article Abstract

Objective: To evaluate the effectiveness of olanzapine versus aripiprazole in patients with schizophrenia.

Method: Patients aged 18 to 65 years with schizophrenia (diagnosed according to DSM-IV-TR criteria) were randomly assigned to either olanzapine (n = 281) or aripiprazole (n = 285) for 28 weeks of double-blind treatment. The primary outcome was time to all-cause discontinuation. Efficacy was measured by Positive and Negative Syndrome Scale (PANSS) total change from baseline. Time-to-event data were analyzed via the Kaplan-Meier method. The study was conducted from October 2003 to July 2007.

Results: Treatment groups did not differ significantly in time to all-cause discontinuation (p =.067) or all-cause discontinuation rate (olanzapine, 42.7% vs. aripiprazole, 50.2%; p =.053). Olanzapine-treated patients had significantly longer time to efficacy-related discontinuation (p < 100 mg/dL and ≥ 126 mg/dL at any time was 1.7% for olanzapine and 0.6% for aripiprazole (p =.623). Fasting mean total cholesterol change was +4.09 mg/dL for olanzapine and -9.85 mg/dL for aripiprazole (p < 200 mg/dL and ≥ 240 mg/dL at any time was 9.2% for olanzapine and 1.5% for aripiprazole (p =.008). Fasting mean triglycerides change was +25.66 mg/dL for olanzapine and -17.52 mg/dL for aripiprazole (p

Conclusion: Treatment groups did not differ significantly on the primary outcome. Olanzapine-treated patients had significantly greater improvement in symptom efficacy at 28 weeks as well as significantly greater mean increases in weight and glucose and significantly greater worsening on lipids parameters.

Trial Registration: Identifier: NCT00088049

Volume: 70

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...